Combinatorial roles of nuclear receptors in inflammation and immunity

Nature Reviews Immunology

Volumn 6, Issue 1, 2006, Pages 44-55

  Glass, Christopher K ^a   Ogawa, Sumito ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CELL NUCLEUS RECEPTOR; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GW 3695; GW 3965; HORMONE RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; REPRESSOR PROTEIN; RETINOID; RETINOID X RECEPTOR; RETINOID X RECEPTOR AGONIST; T 1317; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; ASTHMA; CHRONIC INFLAMMATION; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG SAFETY; DYSLIPIDEMIA; ECZEMA; ENTERITIS; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GRAFT REJECTION; HERPES SIMPLEX; HOMEOSTASIS; HUMAN; HYPERTENSION; IMMUNITY; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE; MACROPHAGE; MEDICAL DOCUMENTATION; METABOLIC REGULATION; MOLECULAR MECHANICS; MUSCLE WEAKNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION INITIATION; VASCULAR FRAGILITY;

ANIMALS; CELL NUCLEUS; DNA-BINDING PROTEINS; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, GLUCOCORTICOID;

EID: 33244482536     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1748     Document Type: Review

References (130)

1. Evans, R. M. The steroid and thyroid hormone receptor superfamily. Science 240, 889-895 (1988).
2. Chawla, A., Repa, J., Evans, R. & Mangelsdorf, D. Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870 (2001).
3. Kastner, P., Mark, M. & Chambon, P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 83, 859-869 (1995).
4. Mangelsdorf, D. J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835-839 (1995).
5. Kliewer, S. A., Umesono, K., Mangelsdorf, D. J. & Evans, R. M. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355, 446-449 (1992).
6. Yu, V. C. et al. RXRβ: a coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell 67, 1251-1266 (1991).
7. Näär, A. M. et al. The orientation and spacing of core DMA-binding motifs dictate selective transcriptional responses to three nuclear receptors. Cell 65, 1267-1279 (1991).
8. Umesono, K. & Evans, R. M. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 57, 1139-1146 (1989).
9. Umesono, K., Murakami, K. K., Thompson, C. C. & Evans, R. M. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65, 1255-1266 (1991).
10. Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H. & Moras, D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375, 377-382 (1995).
11. Moras, D. & Gronemeyer, H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell. Biol. 10, 384-391 (1998).
12. Renaud, J.-P. et al. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378, 681-689 (1995).
13. Wagner, R. L. et al. A structural role for hormone in the thyroid hormone receptor. Nature 378, 690-697 (1995).
14. Heery, D. M., Kalkhoven, E., Hoare, S. & Parker, M. G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387, 733-736 (1997).
15. Torchia, J. et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387, 677-684 (1997).
16. Ding, X. F. et al. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol. Endocrinol. 12, 302-313 (1998).
17. Nolte, R. T. et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395, 137-143 (1998).
18. Shiau, A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937 (1998).
19. Darimont, B. D. et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 12, 3343-3356 (1998).
20. Chen, J. D. & Evans, R. M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377, 454-457 (1995).
21. Horlein, A. J. et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377, 397-404 (1995).
22. Hu, X. & Lazar, M. The CoRNR motif controls the recruitment of compressors by nuclear hormone receptors. Nature 402, 93-96 (1999).
23. Perissi, S. et al. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 13, 3198-3208 (1999).
24. Webb, P. et al. The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). Mol. Endocrinol. 14, 1976-1985 (2000).
25. Xu, H. E. et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα. Nature 415, 813-817 (2002).
26. Brzozowski, A. M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758 (1997).
27. Kliewer, S. A. et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl Acad. Sci. USA 94, 4318-4323 (1997).
28. Forman, B. M., Chen, J. & Evans, R. M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl Acad. Sci. USA 94, 4312-4317 (1997).
29. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803-812 (1995).
30. 2 metabolite binds peroxisome proliferator-activated receptorγ and promotes adipocyte differentiation. Cell 83, 813-819 (1995).
31. Nagy, L., Tontonoz, P., Alvarez, J. G. A., Chen, H. & Evans, R. M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93, 229-240 (1998).
32. Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R. & Mangelsdorf, D. J. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature 383, 728-731 (1996).
33. Janowski, B. A. et al. Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ. Proc. Natl Acad. Sci. USA 96, 266-271 (1999).
34. Lehmann, J. M. et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272, 3137-3140 (1997).
35. Glass, C. K. & Rosenfeld, M. G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14, 121-141 (2000).
36. McKenna, N. J. & O'Malley, B. W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108, 465-474 (2002).
37. Smith, C. L. & O'Malley, B. W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45-71 (2004).
38. Lee, D. Y., Teyssier, C., Strahl, B. D. & Stallcup, M. R. Role of protein methylation in regulation of transcription. Endocr. Rev. 26, 147-170 (2005).
39. Spiegelman, B. M. & Heinrich, R. Biological control through regulated transcriptional coactivators. Cell 119, 157-167 (2004).
40. Damm, K., Thompson, C. C. & Evans, R. M. Protein encoded by v-erbA functions as a thyroid-hormone antagonist. Nature 339, 593-597 (1989).
41. Sap, J., Munoz, A., Schmitt, J., Stunnenberg, H. & Vennstrom, B. Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product. Nature 340, 242-244 (1989).
42. Zhang, J., Kalkum, M., Chait, B. T. & Roeder, R. G. The N-CoR-HDACS nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol. Cell 9, 611-623 (2002).
43. Li, J. et al. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19, 4342-4350 (2000).
44. Guenther, M., Lane, W., Fischle, W., Verdin, E. & Lazar, M. A Core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev. 14, 1048-1057 (2000).
45. Yoon, H. G. et al. Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J. 22, 1336-1346 (2003).
46. Perissi, V., Aggarwal, A., Glass, C. K., Rose, D. W. & Rosenfeld, M. G. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 116, 511-526 (2004). This paper reports that transcriptional activation mediated by ligand-bound nuclear receptors requires the actions of TBL1 and TBLR1. TBLR1 is shown to function as a specific adaptor for the recruitment of the ubiquitin-conjugating-1 9S-proteasome complex required for the exchange of the nuclear-receptor co-repressors NCoR or SMRT for co-activators.
47. Helmberg, A., Auphan, N., Caelles, C. & Karin, M. Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBOJ. 14, 452-460 (1995).
48. Jonat, C., Rahmsdorf, H. J., Park, K.K., Ponta, H. & Herrlich, P. Anti-tumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62, 1189-1204 (1990).
49. Ray, A. & Prefontaine, K. E. Physical association and function antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc. Natl Acad. Sci. USA 91, 752-756 (1994).
50. Schule, R. et al. Retinoicacid is a negative regulator of AP-1-responsive genes. Proc. Natl Acad. Sci. USA 88, 6092-6096 (1991).
51. Yang-Yen, H.F. et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62, 1205-1215 (1990).
52. Scheinman, R. I., Cogswell, P. C., Lofquist, A. K. & Baldwin, A. S. J. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270, 283-286 (1995).
53. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A. & Karin, M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270, 286-290 (1995).
54. Caelles, C., Gonzales-Sancho, J. M. & Munoz, A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev. 11, 3351-3364 (1997).
55. Kamei, Y. et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85, 403-414 (1996).
56. Sheppard, K. A. et al. Nuclear integration of glucocorticoid receptor and nuclear factor-κB signaling by CREB-binding protein and steroid receptor coactivator-1. J. Biol. Chem. 273, 29291-29294 (1998).
57. Scheinman, R. I., Gualberto, A., Jewell, C. M., Cidlowski, J. A. & Baldwin, A. S. Jr. Characterization of mechanisms involved in transrepression of NF-κB activated glucocorticoid receptors. Mol. Cell. Biol. 15, 242-244 (1995).
58. Luecke, H. F. & Yamamoto, K. R. The glucocorticoid receptor blocks P-TEFb recruitment by NFκB to effect promoter-specific transcriptional repression. Genes Dev. 19, 1116-1127 (2005). This paper reports that alternative co-activator requirements at two NF-κB-responsive genes accounts for their differential regulation by glucocorticoid receptor.
59. De Bosscher, K. et al. Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc. Natl Acad. Sci. USA 97, 3919-3924 (2000).
60. Nissen, R. M. & Yamamoto, K. R. The glucocorticoid receptor inhibits NF-κB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 14, 2314-2329 (2000).
61. De Bosscher, K., Vanden Berghe, W. & Haegeman, G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24, 488-522 (2003).
62. Galon, J. et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16, 61-71 (2002).
63. Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J. & Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nature Med. 9, 213-219 (2003). This paper is the first to report that LXRs and their ligands are negative regulators of macrophage inflammatory gene expression.
64. Welch, J. S., Ricote, M., Akiyama, T. E., Gonzalez, F. J. & Glass, C. K. PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFNγ target genes in macrophages. Proc. Natl Acad. Sci. USA 100, 6712-6717 (2003).
65. Ogawa, S. et al. Molecular determinants of crosstalk between nuclear receptors and Toll-like receptors. Cell 122, 707-21 (2005). This paper reports a genome-wide analysis of counter-regulation of TLR signalling by nuclear receptors. Glucocorticoid receptor, PPARγ and LXRs were shown to repress TLR signalling in a receptor-, promoter- and signal-specific manner.
66. Lee, S. K., Kim, J. H., Lee, Y. C., Cheong, J. & Lee, J. W. Silencing mediator of retinoic acid and thyroid hormone receptors, as a novel transcriptional corepressor molecule of activating protein-1, nuclear factor-κB, and serum response factor. J. Biol. Chem. 275, 12470-12474 (2000).
67. Ogawa, S. et al. A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1 -dependent gene networks required for macrophage activation. Proc. Natl Acad. Sci. USA 101, 14461-14466 (2004). This paper reports a general role for NCoR as a co-represser of subsets of inflammatory response genes in macrophages. Molecular analysis of AP1 target genes showed an essential role for JUN in NCoR recruitment.
68. Hoberg, J. E., Yeung, F. & Mayo, M. W. SMRT derepression by the IκB kinase α; A prerequisite to NF-κB transcription and survival. Mol. Cell 16, 245-255 (2004). This paper reports that NF-κB transcription requires IKKα to phosphorylate SMRT on chromatin, stimulating the proteasome-dependent exchange of co-repressor for co-activator complexes.
69. Kelly, D. et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPARγ and RelA. Nature Immunol. 5, 104-112 (2004). This paper describes an anti-inflammatory mechanism, activated by non-pathogenic bacteria, that selectively antagonizes NF-κB in gut epithelial cells. Bacteroides thetaiotaomicron is shown to target transcriptionally active p65, increasing its nuclear export in a PPARγ-dependent manner.
70. Syrovets, T., Schule, A., Jendrach, M., Buchele, B. & Simmet, T. Ciglitazone inhibits plasmin-induced proinflammatory monocyte activation via modulation of p38 MAP kinase activity. Thromb. Haemost. 88, 274-281 (2002).
71. Lee, C. H. et al. Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science 302, 453-457 (2003). This paper reports a pro-inflammatory role for unliganded PPARδ and an anti-inflammatory role for ligand-bound PPARγ in the macrophage.
72. Delerive, P. et al. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J. Biol. Chem. 274, 32048-53204 (1999).
73. Pascual, G. et al. PPARγ-dependent repression of inflammatory response genes mediated by an evolutionary conserved sumoylation-dependent pathway. Nature 437, 759-763 (2005). This paper reports the identification of a sumoylation- and NCoR-dependent pathway by which PPARγ represses the transcriptional activation of inflammatory-response genes in macrophages.
74. Leung, T. H., Hoffmann, A. & Baltimore, D. One nucleotide in a κB site can determine cofactor specificity for NF-κB dimers. Cell 118, 453-464 (2004). Using lentivirus-based methodology, this paper shows that in genes with two NF-κB-binding sites, both sites are required for activity and they can function together as a module to regulate gene activation. The specific NF-κB sequence further dictates the co-activator requirements for gene activation, indicating a direct role for the κB element as an allosteric regulator of NF-κB.
75. Schimmer, B. & Parker, K., in Goodman and Gilman's Pharmacological Basis of Therapeutics (eds Hardman, J. G. & Limbird, L. E.) (McGraw Hill, New York, 1996).
76. Reichardt, H. M. et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 20, 7168-7173 (2001).
77. Reichardt, H. M. et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93, 531-541 (1998).
78. McKay, L. I. & Cidlowski, J. A. Molecular control of immune/inflammatory responses: interactions between nuclear factor-κB and steroid receptor-signaling pathways. Endocr. Rev. 20, 435-459 (1999).
79. Adcock, I. M. & Barnes, P. J. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation. Biochem. Soc. Trans. 24, 267S (1996).
80. Joyce, D. A., Steer, J. H. & Abraham, L. J. Glucocorticoid modulation of human monocyte/macrophage function: control of TNF-α secretion. Inflamm. Res. 46, 447-451 (1997).
81. Almawi, W. Y., Beyhum, H. N., Rahme, A. A. & Rieder, M. J. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J. Leukoc. Biol. 60, 563-72 (1996).
82. Kleinert, H., Euchenhofer, C., Ihrig-Biedert, I. & Forstermann, U. Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-κB. Mol. Pharmacol. 49, 15-21 (1996).
83. Tanaka, J. & Fujita, H. Glucocorticoid- and mineralocorticoid receptors in microgial cells: the two receptors mediate differential effects of corticosteroids. Glia 20, 23-27 (1997).
84. Koehler, L., Hass, R., DeWitt, D. L., Resch, K. & Goppelt-Struebe, M. Glucocorticoid-induced reduction of prostanoid synthesis in TPA- differentiated U937 cells is mainly due to a reduced cyclooxygenase activity. Biochem. Pharmacol. 40, 1307-1316 (1990).
85. Lund, J., Sato, A., Akira, S., Medzhitov, R. & Iwasaki, A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198, 513-520 (2003).
86. Krug, A. et al. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 103, 1433-1437 (2004).
87. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. & Glass, C. K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79-82 (1998).
88. Jiang, C., Ting, A. T. & Seed, B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86 (1998).
89. Chinetti, G. et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273, 25573-25580 (1998).
90. Jones, D. C., Ding, X. & Daynes, R. A. Nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is expressed in resting murine lymphocytes. The PPARα in T and B lymphocytes is both transactivation and transrepression competent. J. Biol. Chem. 277, 6838-6845 (2002).
91. Cunard, R. et al. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. 168, 2795-2802 (2002).
92. Clark, R. B. et al. The nuclear receptor PRARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J. Immunol. 164, 1364-1371 (2000).
93. Setoguchi, K. et al. Peroxisome proliferator-activated receptor-γ haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J. Clin. Invest. 108, 1667-1675 (2001).
94. Gosset, P. et al. Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cells. Eur. J. Immunol. 31, 2857-2865 (2001).
95. Faveeuw, C. et al. Peroxisome proliferator-activated receptor-γ activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett. 486, 261-266 (2000).
96. Szatmari, I. et al. Activation of PPARγ specifies a dendritic cell subtype capable of enhanced induction of iNKTcell expansion. Immunity 21, 95-106 (2004).
97. Delerive, P. et al. Peroxisome proliferator-activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 85, 394-402 (1999).
98. Jackson, S. M. et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 19, 2094-2104 (1999).
99. Marx, N., Sukhova, G. K., Collins, T., Libby, P. & Plutzky, J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99, 3125-3131 (1999).
100. 4 pathway to inflammation control. Nature 384, 39-43 (1996).
101. Staels, B. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393, 790-793 (1998).
102. Castrillo, A. & Tontonoz, P. PPARs in atherosclerosis: the clot thickens. J. Clin. Invest. 114, 1538-1540 (2004).
103. Valledor, A. F. & Ricote, M. Nuclear receptor signaling in macrophages. Biochem. Pharmacol. 67, 201-212 (2004).
104. Daynes, R. A. & Jones, D. C. Emerging roles of PPARs in inflammation and immunity. Nature Rev. Immunol. 2, 748-759 (2002).
105. Genolet, R., Wahli, W. & Michalik, L. PPARs as drug targets to modulate inflammatory responses? Curr. Drug Targets Inflamm. Allergy 3, 361-375 (2004).
106. 3 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl Acad. Sci. USA 97, 4844-4849 (2000).
107. Rossi, A. et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403, 103-108 (2000).
108. Peet, D. J., Janowski, B. A. & Mangelsdorf, D. J. The LXRs: a new class of oxysterol receptors. Curr. Opin. Genet. Dev. 8, 571-575 (1998).
109. Venkateswaran, A. et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα. Proc. Natl Acad. Sci. USA 97, 12097-12102 (2000).
110. Laffitte, B. A. et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl Acad. Sci. USA 98, 507-512 (2001).
111. Joseph, S. B. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl Acad. Sci. USA 99, 7604-7609 (2002).
112. Tangirala, R. K. et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl Acad. Sci. USA 99, 11896-11901 (2002).
113. Castrillo, A., Joseph, S. B., Marathe, C., Mangelsdorf, D. J. & Tontonoz, P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J.Biol. Chem. 278, 10443-10449 (2003).
114. Valledor, A. F. et al. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc. Natl Acad. Sci. USA 101, 17813-17818 (2004). This paper reports that activation of LXRs and RXRs protect macrophages from apoptosis caused by infection with B. anthracis, E. coli or S. typhimurium.
115. Joseph, S. B. et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119, 299-309 (2004). This paper reports that mice lacking LXRs are highly susceptible to infection with the intracellular bacterium L. monocytogenes, because of increased macrophage apoptosis.
116. Castrillo, A. et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell 12, 805-816 (2003). This paper provides evidence that microbial pathogens interfere with macrophage cholesterol metabolism through inhibition of the LXR signaling pathway. Activation of TLR3 or TLR4 blocked the induction of LXR target genes in cultured macrophages, as well as in aortic tissue in vivo.
117. Chen, Z. et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. 21, 372-377 (2001).
118. Claudel, T. et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl Acad. Sci. USA 98, 2610-2615 (2001).
119. Collins, A. R. et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21, 365-371 (2001).
120. Li, A. C. et al. Differential inhibition of macrophage foam cell formation and atherosclerosis in mice by PPAR α, β/δ, and γ. J. Clin. Invest. 114, 1564-1576 (2004).
121. Li, A. et al. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106, 523-531 (2000).
122. Desreumaux, P. et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPARγ) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. 193, 827-838 (2001).
123. Su, C. G. et al. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J. Clin. Invest 104, 383-389 (1999).
124. Feinstein, D. L. et al. Peroxisome proliferator-activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51, 694-702 (2002).
125. 2 ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168, 2508-2515 (2002).
126. Ellis, C. N. et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-γ inhibit keratinocyte proliferation. Arch. Dermatol. 136, 609-616 (2000).
127. Lewis, J. D. & Lichetenstein, G. R. An open-label trial of the PPAR-γ ligand rosiglitazone for active ulcerative colitis. Am. J. Gastroenterol. 96, 3323-3328 (2001).
128. Kornbluth, A. What happened to drug trials in ulcerative colitis? Problems, PPARs, placebos, and (possible) progress. Am. J. Gastroenterol. 96, 3232-3234 (2001).
129. Wagner, B. L. et al. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell. Biol. 23, 5780-5789 (2003).
130. Barish, G. D. et al. A nuclear receptor atlas: macrophage activation. Mol. Endocrinol. 19, 2466-2477 (2005). This paper reports the use of quantitative real-time PCR to provide a comprehensive assessment of changes in expression of the 49 members of the mouse nuclear-receptor superfamily in macrophages.